Roche (OTCMKTS:RHHBY) Stock Passes Below 50-Day Moving Average - What's Next?

Key Points

• Roche shares fell below their 50-day moving average, trading as low as $52.90 versus the $54.43 average, before last changing hands at $53.19.
• Analyst sentiment remains generally positive: Roche has an average “Moderate Buy” rating and a $60.00 consensus price target, with recent upgrades from Morgan Stanley and Royal Bank of Canada.
• Several institutional investors increased their Roche holdings in recent quarters, while the company continues to operate across its Pharmaceuticals and Diagnostics divisions.

Roche Holding AG (OTCMKTS:RHHBY - Get Free Report)'s share price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $54.43 and traded as low as $52.90. Roche shares last traded at $53.19, with a volume of 1,488,714 shares traded.

Analyst Upgrades and Downgrades

RHHBY has been the subject of several recent analyst reports. HSBC reiterated a "hold" rating on shares of Roche in a research note on Thursday. Morgan Stanley raised shares of Roche from an "equal weight" rating to an "overweight" rating and set a $63.00 price target on the stock in a research report on Friday, August 7th. Royal Bank Of Canada began coverage on shares of Roche in a research report on Tuesday. They issued an "outperform" rating for the company. Finally, Zacks Research raised shares of Roche from a "strong sell" rating to a "hold" rating in a research report on Monday, August 24th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Roche has an average rating of "Moderate Buy" and an average target price of $60.00.

Roche Price Performance

The company has a current ratio of 1.38, a quick ratio of 1.12 and a debt-to-equity ratio of 0.72. The firm has a fifty day simple moving average of $54.43 and a two-hundred day simple moving average of $52.62.

Institutional Trading of Roche

A number of institutional investors have recently modified their holdings of RHHBY. Verity Asset Management Inc. grew its stake in Roche by 20.9% in the 3rd quarter. Verity Asset Management Inc. now owns 10,990 shares of the company's stock valued at $459,000 after buying an additional 1,898 shares in the last quarter. Hancock Whitney Corp lifted its position in shares of Roche by 4.8% during the third quarter. Hancock Whitney Corp now owns 24,488 shares of the company's stock worth $1,024,000 after acquiring an additional 1,116 shares in the last quarter. HighPoint Advisor Group LLC boosted its holdings in shares of Roche by 55.3% in the fourth quarter. HighPoint Advisor Group LLC now owns 16,515 shares of the company's stock worth $852,000 after acquiring an additional 5,882 shares during the period. S&CO Inc. boosted its holdings in shares of Roche by 2.5% in the fourth quarter. S&CO Inc. now owns 53,444 shares of the company's stock worth $2,767,000 after acquiring an additional 1,290 shares during the period. Finally, PNC Financial Services Group Inc. grew its position in shares of Roche by 18.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 22,255 shares of the company's stock valued at $1,148,000 after purchasing an additional 3,456 shares in the last quarter.

Roche Company Profile

Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.

The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.